Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and etoposide with or without bevacizumab in first-line extensive-stage small cell lung cancer
2007-007949-13Phase 3Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Oct 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, cisplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Overall survival. Started Oct 2008; status: completed.
02
Drugs
bevacizumabcisplatinetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2007-007949-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007949-13.